Targeting C-type lectin receptors: A high-carbohydrate diet for dendritic cells to improve cancer vaccines

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigenspecific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.

Original languageEnglish
Pages (from-to)1017-1034
Number of pages18
JournalJournal of Leukocyte Biology
Volume102
Issue number4
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

@article{cb5cfe62711842f7bd616a31ab34d45d,
title = "Targeting C-type lectin receptors: A high-carbohydrate diet for dendritic cells to improve cancer vaccines",
abstract = "There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigenspecific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.",
keywords = "Antigen presentation, Antigen presenting cells, Macrophages, T cells",
author = "{van Dinther}, Dieke and Stolk, {Dorian A.} and {van de Ven}, Rieneke and {van Kooyk}, Yvette and {de Gruij}, {Tanja D.} and {den Haan}, {Joke M.M.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1189/jlb.5MR0217-059RR",
language = "English",
volume = "102",
pages = "1017--1034",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "4",

}

Targeting C-type lectin receptors : A high-carbohydrate diet for dendritic cells to improve cancer vaccines. / van Dinther, Dieke; Stolk, Dorian A.; van de Ven, Rieneke; van Kooyk, Yvette; de Gruij, Tanja D.; den Haan, Joke M.M.

In: Journal of Leukocyte Biology, Vol. 102, No. 4, 01.10.2017, p. 1017-1034.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Targeting C-type lectin receptors

T2 - A high-carbohydrate diet for dendritic cells to improve cancer vaccines

AU - van Dinther, Dieke

AU - Stolk, Dorian A.

AU - van de Ven, Rieneke

AU - van Kooyk, Yvette

AU - de Gruij, Tanja D.

AU - den Haan, Joke M.M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigenspecific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.

AB - There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigenspecific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.

KW - Antigen presentation

KW - Antigen presenting cells

KW - Macrophages

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85030658050&partnerID=8YFLogxK

U2 - 10.1189/jlb.5MR0217-059RR

DO - 10.1189/jlb.5MR0217-059RR

M3 - Review article

VL - 102

SP - 1017

EP - 1034

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 4

ER -